Suppr超能文献

思然®全润滴眼液治疗隐形眼镜不适的应用。

Application of systane complete for the treatment of contact lens discomfort.

机构信息

University of Alabama at Birmingham, Birmingham, AL, United States.

University of Alabama at Birmingham, Birmingham, AL, United States.

出版信息

Cont Lens Anterior Eye. 2021 Aug;44(4):101399. doi: 10.1016/j.clae.2020.12.004. Epub 2020 Dec 13.

Abstract

PURPOSE

To understand the safety of treating contact lens (CL) discomfort with a new artificial tear when it is directly applied to a CL-wearing eye.

METHODS

This was a two-week, two-visit, double-masked study that randomized participants with CL discomfort to use Systane Complete (artificial tear), Sensitive Eyes (rewetting drop), or no treatment. Drops were applied before, twice during, and after CL use each day. Corneal staining served as the primary safety metric. Conjunctival staining, tear break-up time, Schirmer's test, CL comfort (Contact Lens Dry Eye Questionnaire-8 [CLDEQ-8]), and dry eye symptoms (Standardized Patient Evaluation of Eye Dryness [SPEED]) were also evaluated.

RESULTS

This study recruited 73 participants with a mean age of 30.3 ± 11.5 years; 18 % of the participants were male. There were no significant changes in ocular surface signs from baseline or between the artificial tear and rewetting drop groups after two weeks (p ≥ 0.05). Participants in the artificial tear and rewetting drop groups had significant improvements in CLDEQ-8 scores after two weeks of treatment compared with baseline (p < 0.0001), though scores for this test were not significantly different between these groups after two weeks (p = 0.94). CLDEQ-8 scores were significantly better in the artificial tear and rewetting drop groups compared with no treatment after two weeks (p < 0.0001).

CONCLUSIONS

Both drops were found to be safe for use with CLs while also significantly improving ocular symptoms compared to no treatment after two weeks of use.

摘要

目的

了解将一种新的人工泪液直接应用于戴隐形眼镜的眼睛以治疗隐形眼镜不适的安全性。

方法

这是一项为期两周、两次就诊、双盲研究,将隐形眼镜不适的参与者随机分为使用 Systane Complete(人工泪液)、Sensitive Eyes(润湿滴剂)或不治疗的三组。每天在戴隐形眼镜之前、两次戴隐形眼镜期间和之后滴用眼药水。角膜染色是主要的安全性指标。还评估了结膜染色、泪膜破裂时间、泪液分泌试验、隐形眼镜舒适度(隐形眼镜干眼症问卷-8 [CLDEQ-8])和干眼症症状(标准化患者眼干燥评估 [SPEED])。

结果

这项研究招募了 73 名平均年龄为 30.3 ± 11.5 岁的参与者;18%的参与者为男性。两周后,与基线相比或在人工泪液和润湿滴剂组之间,眼表面体征没有明显变化(p ≥ 0.05)。与基线相比,在两周的治疗后,人工泪液和润湿滴剂组的 CLDEQ-8 评分均显著改善(p<0.0001),尽管两组之间两周后该测试的评分没有显著差异(p=0.94)。与不治疗相比,两周后人工泪液和润湿滴剂组的 CLDEQ-8 评分均显著更好(p<0.0001)。

结论

两种滴剂在与隐形眼镜一起使用时均被发现是安全的,并且在两周的使用后与不治疗相比,显著改善了眼部症状。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验